LOS ANGELES, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd., a clinical stage biopharmaceutical company developing cancer therapeutics designed to reverse cancer drug resistance and immune...
TORONTO, Aug. 9, 2023 /CNW/ - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has issued a Notice of Compliance (NOC) authorizing the use of ERLEADA® (apalutamide) in an additional strength of a 240mg tablet. ERLEADA® 240 mg is now the only once-daily, single-tablet Androgen Receptor Inhibitor (ARI) approved by Health Canada for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC) as well as patients with non-metastatic castration-resistant prostate cancer (nmCRPC).1
HORSHAM, Pa., April 3, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the availability of an additional tablet strength of ERLEADA® (apalutamide) in the United States. The introduction of the 240mg tablet provides the first-and-only option for a once-daily, single-tablet Androgen Receptor Inhibitor (ARI) approved for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).
The United States’ Food and Drug Administration (FDA) has approved twice-a-year injections and tablets for treating HIV in adults with multi-drug resistant infection.
A group of plaintiffs, including J&J’s Janssen unit and the Sloan Kettering Institute for Cancer Research, filed a lawsuit against Aurobindo on Thursday accusing it of applying to market an Erleada copycat before five patents are up.
FDA Confirms Para IV Patent Litigation for Apalutamide tablets.
SAN FRANCISCO, Feb. 14, 2022 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world evidence data showing the initiation of ERLEADA® (apalutamide) results in high rates of rapid and deep prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC). In a separate post-hoc analysis of the registrational Phase 3 SPARTAN and TITAN studies, rapid and deep PSA responses with ERLEADA® were associated with improvement in patient-reported outcomes (PROs) related to quality of life, physical wellbeing, pain, and fatigue intensity. These findings will be presented during the American Society of Clinical Oncology's Genitourinary (ASCO GU) Cancers Symposium, taking place in San Francisco and virtually from February 17-19, 2022.
Johnson & Johnson (J&J) has announced plans to spin off its Consumer Health unit from its Pharmaceutical and Medical Device business, creating two independent publicly traded companies.
The UK’s National Institute of Health and Care Excellence (NICE) has recommended Janssen’s Erleada (apalutamide)for the treatment of prostate cancer, after previously rejecting the therapy.
The US Food and Drug Administration (FDA) on Friday finalized guidance on the use of metastasis-free survival (MFS) as an endpoint in clinical trials for nonmetastatic castration-resistant prostate cancer (nmCRPC).